174 related articles for article (PubMed ID: 21997468)
1. Modeling red blood cell survival data.
Korell J; Vos FE; Coulter CV; Schollum JB; Walker RJ; Duffull SB
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):787-801. PubMed ID: 21997468
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of red blood cell labelling methods based on a statistical model for red blood cell survival.
Korell J; Coulter CV; Duffull SB
J Theor Biol; 2011 Dec; 291():88-98. PubMed ID: 21945607
[TBL] [Abstract][Full Text] [Related]
3. Red blood cell survival in long-term dialysis patients.
Vos FE; Schollum JB; Coulter CV; Doyle TC; Duffull SB; Walker RJ
Am J Kidney Dis; 2011 Oct; 58(4):591-8. PubMed ID: 21715072
[TBL] [Abstract][Full Text] [Related]
4. Red blood cell survival in chronic renal failure.
Ly J; Marticorena R; Donnelly S
Am J Kidney Dis; 2004 Oct; 44(4):715-9. PubMed ID: 15384023
[TBL] [Abstract][Full Text] [Related]
5. Shortened red blood cell age in patients with end-stage renal disease who were receiving haemodialysis: a cross-sectional study.
Matsumura K; Okumiya T; Sugiura T; Takahashi N; Yamamoto Y; Kikuchi S; Fujii K; Otagaki M; Shiojima I
BMC Nephrol; 2020 Sep; 21(1):418. PubMed ID: 32993543
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell calcium homeostasis in patients with end-stage renal disease.
Gafter U; Malachi T; Barak H; Djaldetti M; Levi J
J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934
[TBL] [Abstract][Full Text] [Related]
7. Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Blood Purif; 2008; 26(3):267-73. PubMed ID: 18417959
[TBL] [Abstract][Full Text] [Related]
8. A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.
Korell J; Duffull SB
J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):469-78. PubMed ID: 23775141
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.
Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Papageorgiou EG; Voulgaridou AI; Kokkalis AC; Antonelou MH; Papassideri IS
Eur J Haematol; 2017 Jun; 98(6):590-600. PubMed ID: 28295628
[TBL] [Abstract][Full Text] [Related]
10. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
11. Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease.
Li JH; Luo JF; Jiang Y; Ma YJ; Ji YQ; Zhu GL; Zhou C; Chu HW; Zhang HD
Kidney Blood Press Res; 2019; 44(5):1158-1165. PubMed ID: 31550724
[TBL] [Abstract][Full Text] [Related]
12. Is erythropoietin a survival factor for red blood cells?
Polenakovic M; Sikole A
J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
[TBL] [Abstract][Full Text] [Related]
13. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease.
Artunc F; Risler T
Nephrol Dial Transplant; 2007 Oct; 22(10):2900-8. PubMed ID: 17556407
[TBL] [Abstract][Full Text] [Related]
14. [The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure].
Olszewska M
Ann Acad Med Stetin; 2004; 50(1):41-52. PubMed ID: 16871743
[TBL] [Abstract][Full Text] [Related]
15. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin and anemia in chronic renal failure.
Pavlović-Kentera V; Clemons GK; Djukanović L; Biljanović-Paunovic L
Exp Hematol; 1987 Aug; 15(7):785-9. PubMed ID: 3609182
[TBL] [Abstract][Full Text] [Related]
17. Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure.
Himmelfarb J; McMonagle E; Holbrook D; Hakim R
Kidney Int; 1999 Feb; 55(2):659-66. PubMed ID: 9987090
[TBL] [Abstract][Full Text] [Related]
18. Neocytolysis contributes to the anemia of renal disease.
Rice L; Alfrey CP; Driscoll T; Whitley CE; Hachey DL; Suki W
Am J Kidney Dis; 1999 Jan; 33(1):59-62. PubMed ID: 9915268
[TBL] [Abstract][Full Text] [Related]
19. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis.
Sato Y; Mizuguchi T; Shigenaga S; Yoshikawa E; Chujo K; Minakuchi J; Kawashima S
Ther Apher Dial; 2012 Dec; 16(6):522-8. PubMed ID: 23190511
[TBL] [Abstract][Full Text] [Related]
20. High cumulative incidence of cancer in patients with cardio-renal-anaemia syndrome.
Schroten NF; van der Putten K; Rutten FH; Diepenbroek A; Mosterd A; Gaillard CA
Eur J Heart Fail; 2010 Aug; 12(8):855-60. PubMed ID: 20495204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
